Skip to content

STEMLINE THERAPEUTICS INC: 10-K filed 2014-03-31

What STEMLINE THERAPEUTICS INC reported in its annual report filed 2014-03-31 (fiscal FY 2013): 24 published measures, 82 facts as tagged in accession 0001104659-14-024493.

This filing

Form
10-K (annual report)
Filed
2014-03-31
Fiscal period
fiscal FY 2013
Accession
0001104659-14-024493 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All STEMLINE THERAPEUTICS INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-12-3185,281,196USD
At 2012-12-315,029,611USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2013-12-315,656,808USD
At 2012-12-317,538,031USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-12-3179,624,388USD
At 2012-12-31-2,508,420USD
At 2011-12-313,205,340USD
At 2010-12-315,851,561USD
At 2009-12-31-6,162,216USD
At 2008-12-31-3,355,510USD
At 2007-12-31-657,939USD
At 2006-12-311,169,616USD
At 2005-12-311,442,756USD
At 2004-12-311,963,447USD
At 2003-12-31337,069USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-12-3144,200,420USD
At 2012-12-312,025,338USD
At 2011-12-315,829,886USD
At 2010-12-317,226,366USD

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2013-12-31-31,365,766USD
At 2012-12-31-7,169,255USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2013-12-31383,333USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-01-01 to 2013-12-314,847,086USD365
2003-08-08 to 2013-12-317,046,753USD3799
2012-01-01 to 2012-12-31561,022USD366
2011-01-01 to 2011-12-31108,405USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2013-01-01 to 2013-12-31-23,979,463USD365
2003-08-08 to 2013-12-31-44,909,927USD3799
2012-01-01 to 2012-12-31-6,467,573USD366
2011-01-01 to 2011-12-31-2,717,054USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-12-3144,692,951USD
At 2012-12-312,324,427USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2013-01-01 to 2013-12-31516,871USD365
2003-08-08 to 2013-12-31813,821USD3799
2012-01-01 to 2012-12-31118,765USD366
2011-01-01 to 2011-12-3198,643USD365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-12-315,013,808USD
At 2012-12-315,500,735USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2013-01-01 to 2013-12-3124,050,463USD365
2003-08-08 to 2013-12-3144,980,927USD3799
2012-01-01 to 2012-12-316,467,573USD366
2011-01-01 to 2011-12-312,717,054USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2013-01-01 to 2013-12-3116,178,744USD365
2003-08-08 to 2013-12-3127,624,412USD3799
2012-01-01 to 2012-12-313,376,962USD366
2011-01-01 to 2011-12-311,629,026USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-12-3113,095,726shares
At 2012-12-313,476,501shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2013-12-31-43,775USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2013-12-3176,667USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2013-12-315,013,808USD
At 2012-12-315,500,735USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2013-12-31292,916USD
At 2012-12-31299,089USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2013-01-01 to 2013-12-31-24,240,286USD365
2003-08-08 to 2013-12-31-43,581,304USD3799
2012-01-01 to 2012-12-31-6,274,782USD366
2011-01-01 to 2011-12-31-2,754,626USD365

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-7,666,703USD92
2013-01-01 to 2013-12-31-24,196,511USD365
2003-08-08 to 2013-12-31-33,956,929USD3799
2013-07-01 to 2013-09-30-5,573,524USD92
2013-04-01 to 2013-06-30-5,450,638USD91
2013-01-01 to 2013-03-31-5,505,646USD90
2012-10-01 to 2012-12-31-1,294,096USD92
2012-01-01 to 2012-12-31-6,274,782USD366
2012-07-01 to 2012-09-30-1,965,463USD92
2012-04-01 to 2012-06-30-1,844,839USD91
2012-01-01 to 2012-03-31-1,170,384USD91
2011-01-01 to 2011-12-31-2,754,626USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-01-01 to 2013-12-317,871,719USD365
2003-08-08 to 2013-12-3117,356,515USD3799
2012-01-01 to 2012-12-313,090,611USD366
2011-01-01 to 2011-12-311,088,028USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2013-01-01 to 2013-12-3176,667USD365
2003-08-08 to 2013-12-3176,667USD3799

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2013-01-01 to 2013-12-31-11,675,711USD365
2012-01-01 to 2012-12-31-2,837,903USD366
2011-01-01 to 2011-12-31-1,256,659USD365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2013-01-01 to 2013-12-3197,708,506USD365
2003-08-08 to 2013-12-31101,550,788USD3799
2013-05-17 to 2013-05-2264,500,000USD6

Inspect the source

Entity
STEMLINE THERAPEUTICS INC / CIK 0001264587
Captured
SEC response SHA-256
4bc563f579ac3611fca3a4b0f91dded31bf19c0e78ed6a10086fa540610de496

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001264587.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))